Sufficient patient medication knowledge is essential for appropriate
use. The dispensing service provided in community pharmacies is one
method that may be used to educate patients on their medications.
To compare the effectiveness of protocolized dispensing (following a
dispensing protocol that includes standardized patient education), with
the effectiveness of traditional dispensing (provision of medication
without standardized patient education and information provided only if
directly requested), for improving patient medication knowledge.
Pre-post quasi-experimental study of patients or caregivers over
18 years of age requesting one or more medications for their own use or
for others. The intervention consisted of using a protocolized process
for dispensing medicines in a community pharmacy. The association
between the dispensing effectiveness (patient medication knowledge pre
and post dispensing) and predictor variables was studied using a
multivariate binary logistical regression model.
In total 661 participant medication requests were included in the
study. Protocolized dispensing was more effective than traditional
dispensing for improving medication knowledge (OR 2.390; 95 % CI
As a means
to improve patient medication knowledge it may be recommended that
protocolized dispensing processes should be developed, evaluated and
implemented with the ultimate aim of improving the appropriate use of
Community pharmacy services, Dispensing Patient medication knowledge, Spain.
Effectiveness and safety of generic version of abacavir/lamivudine
and efavirenz in treatment naïve HIV-infected patients: a nonrandomized,
open-label, phase IV study in Cali-Colombia, 2011–2012."
Jaime Galindo, Pedro Amariles , Héctor F. Mueses-Marín, Jaime A. Hincapié, Sebastián González-Avendaño, Ximena Galindo-Orrego.
Generic drug policies are
often associated with concerns about the quality and effectiveness of
these products. Phase IV clinical trials may be a suitable design to
assess the effectiveness and safety of generic drugs. The objective of
this study was to describe the effectiveness and the safety of the
generic abacavir/lamivudine and efavirenz in treatment-naïve
A monocentric, nonrandomized,
open-label, phase IV study in treatment naïve HIV-infected patients
18 years or older with indication to receive abacavir/lamivudine and
efavirenz were recruited from a program that provides comprehensive
outpatient consultation and continuing care. The primary end-point was
to achieve viral load <40 copies/mL at 12 months after baseline to
assess effectiveness. Secondary end-point of the study were 1) to asses
increasing in T-CD4 lymphocytes levels as accompaniment to asses
effectiveness, and 2) to assess both gastrointestinal, skin, and central
nervous system symptoms, and lipid profile, cardiovascular risk, renal,
and hepatic function as safety profile. Data were determined at
baseline, 3, 6, and 12 months. Close clinical monitoring and
pharmaceutical care were used for data collection. Wilcoxon
matched-pairs signed-rank test was used to compare proportions or
Sixty patients were invited to
participate in the study; 42 were enrolled and 33 completed the
follow-up. Of the nine patients excluded from the study, only one was
withdrawn due to adverse events. At 12 months, 31 of 42 patients (73.8 %
in intention-to-treat analysis) achieved a viral load of HIV1 RNA
<40 copies/mL. There was a significant increase (172 cells/mm3)
in the median for CD4 T lymphocyte count. The adverse events were mild
and met the safety profile for this antiretroviral regimen, mainly of
central nervous system symptoms, skin rash, lipid abnormalities, and an
increase of 2 % in the median of the percentage of cardiovascular risk.
The clinical outcomes of
generic version of abacavir/lamivudine and efavirenz in HIV treatment
naïve patients showed the expected safety and effectiveness profile of
proprietary ARV drugs.
Registro Público Cubano de Ensayos Clínicos (RPCEC) ID: RPCEC00000202. Registered 19 November 2015.
HIV/AIDSGeneric drugsAntiretroviral drugsPhase IV study
El Grupo de Investigación en Atención Farmacéutica CTS131 de la Universidad de Granada, convoca plazas de Investigadores/as colaboradores/as para la participación en proyectos de investigación durante los cursos académicos 2016-2017, 2017-2018. Se valorará: - Conocimientos en Atención Farmacéutica - Conocimientos en Investigación - Dominio de lengua inglesa - Manejo de herramientas informáticas Los interesados enviarán Curriculum Vitae y situación laboral actual a
Fecha límite de envío 31 de marzo de 2016